SGLT2i and GLP-1RA in Cardiometabolic and Renal Diseases: From Glycemic Control to Adipose Tissue Inflammation and Senescence

Figure 1

Proven benefits of SGLT2i and GLP-1RA in the cardiorenal-vascular axis. Strong evidence supports the multiple effects of SGLT2i and GLP-1RA on the cardiovascular disease scenario. Studies show cardio- and renoprotective properties in clinical biomarkers and long-term mortality. SGLT2i: sodium-glucose cotransporter 2 inhibitors; GLP-1RA: glucagon-like peptide 1 agonists.